Effects of resveratrol pretreatment on tert-butylhydroperoxide induced hepatocyte toxicity in immobilized perifused hepatocytes: involvement of inducible nitric oxide synthase and hemoxygenase-1.
The aim of this work was to study the effects of resveratrol (RES) as compared to silymarin (SM) pretreatments on tert-butylhydroperoxide (tBH) induced apoptotic/necrotic markers in hepatocytes. Hepatocyte in cultures (48 h) and in perifused immobilized agarose threads (5h) were used as cellular systems. Hepatocyte apoptosis was estimated morphologically using Annexin-V combined with propidium iodide, or toluidine blue staining. Hepatocyte viability and functionality were evaluated by ALT and urea synthesis. Nitric oxide (NO) and carbon monoxide involvements were also examined. Resveratrol and silymarin reduced tBH-induced hepatocyte toxic effects in short term experiments (5h) as measured by a significant reduction in ALT and NO increase produced by tBH. Both inducible nitric oxide synthase (NOS-2) and hemoxygenase-1 (HO-1) gene expression were increased by tBH and reduced by both RES and SM pretreatments. Morphologically, there were ameliorations in both apoptotic and necrotic markers under RES treatment and were similar to biochemical findings. In addition, RES improved hepatocyte stability in both cellular systems. It may be concluded that resveratrol and sylimarin ameliorative effects on tBH hepatocyte toxicity are comparable; involve NOS-2 and HO-1 expression and should be re-evaluated in various in vitro and in vivo experimental conditions.
Cerný
Dalibor
D
Institute of Pharmacology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00 Prague 2, Czech Republic.
Canová
Nikolina Kutinová
NK
Martínek
Jindrich
J
Horínek
Ales
A
Kmonícková
Eva
E
Zídek
Zdenek
Z
Farghali
Hassan
H
D000410:Alanine Transaminase / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D014408:Biomarkers, Tumor / Q000378:metabolism; D002478:Cells, Cultured; D018914:Cells, Immobilized; D019610:Cytoprotection; D051547:Heme Oxygenase-1 / Q000378:metabolism*; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012838:Silymarin / Q000494:pharmacology; D013267:Stilbenes / Q000494:pharmacology*; D020122:tert-Butylhydroperoxide / Q000633:toxicity*
D014408:Biomarkers, Tumor; D012838:Silymarin; D013267:Stilbenes; D009569:Nitric Oxide; D020122:tert-Butylhydroperoxide; D052247:Nitric Oxide Synthase Type II; D051547:Heme Oxygenase-1; D000410:Alanine Transaminase; D000077185:Resveratrol